Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verici DxLSE:VRCI FCF Yield % is -78.44 as of Jul. 23, 2026. The stock has 3 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Verici Dx ranks worse than 94.37% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Verici Dx's FCF Yield % or its related term are showing as below:
LSE:VRCI'
s FCF Yield % Range Over the Past 10 Years
Min: -402.41 Med: -109.22 Max: -30.47
Current: -78.44
During the past 6 years, the highest FCF Yield % of Verici Dx was -30.47%. The lowest was -402.41%. And the median was -109.22%.
LSE:VRCI's FCF Yield % is ranked worse than 94.37% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.17
vs LSE:VRCI: -78.44
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Verici Dx FCF Yield % Related Terms
Verici Dx FCF Yield % Historical Data
* Premium members only.
The historical data trend for Verici Dx's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:VRCI vs TMO, DHR, IDXX: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Verici Dx's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Verici Dx's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (LSE:VRCI) has a FCF Yield % of -78.44 as of Jul. 23, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Verici Dx and its competitors. According to the industry distribution chart, Verici Dx ranks #201 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 94.4%.
Is Verici Dx's FCF Yield % too high?
Verici Dx's current FCF Yield % is -78.44. Based on the distribution chart, Verici Dx ranks #201 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Verici Dx's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Verici Dx ranks #201 out of 213 companies for FCF Yield %. This places Verici Dx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Verici Dx and its competitors. Verici Dx's current FCF Yield % is -78.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verici Dx stock overvalued right now?
Verici Dx (LSE:VRCI) has a current FCF Yield % of -78.44. The current FCF Yield % is -78.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Verici Dx (LSE:VRCI), the current FCF Yield % is -78.44 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:VRCI has been successfully added to your 
